NAFE Names Lilly to Top 50 Companies for Executive Women

LillyEli Lilly and Company (NYSE: LLY) has been named to the 2011 NAFE Top 50 Companies for Executive Women by the National Association for Female Executives (NAFE). The list recognizes organizations whose policies and practices encourage women's advancement and whose numbers at the highest levels of leadership demonstrate that commitment. Lilly received the award first in 2009, and again in 2010.

"It truly is an honor to win this award for the third consecutive year," said Shaun Hawkins, chief diversity officer. "At Lilly, we're confident that the acceleration of our commitment to efforts, such as the professional growth and development of executive women, ultimately will lead to better business results and innovative therapies to improve patient outcomes."

The 2011 NAFE Top Companies application includes 225 questions on such topics as female representation, hiring, attrition and promotion rates; access and usage of key retention and advancement programs such as mentoring, executive coaching, networking and sponsorship; company culture; and manager training and accountability. To be considered for the NAFE Top Companies for Executive Women, companies must have a minimum of two women on their board of directors as well as at least 500 employees in the U.S.

"Women have long struggled to reach the highest ranks in a male-dominated business environment, but with the growing profitability of companies with women in the top ranks, that is changing," said Dr. Betty Spence, NAFE president. "Today, employers reward the skills that women bring and demand them of men, as well."

NAFE will honor each of the top companies at a gala luncheon in New York City on March 30. A report will be published in NAFE magazine and also is available online on NAFE's website.

Additional diversity awards received by Lilly in 2010 and 2011 include:

  • DiversityInc's 2011 "Top 50 Companies for Diversity"
  • Careers & the disABLED magazine's 2010 "Top 50 Employers"
  • Working Mother magazine's 2010 "Top 100 Best Places to Work"

About NAFE
The National Association for Female Executives (NAFE), founded in 1972, serves 20,000 members nationwide with networking, tools and solutions to strengthen and grow their careers and businesses. NAFE magazine publishes the annual Top Companies issue and the annual Women of Excellence issue. NAFE.com provides up-to-date information, community for women in business and access to member benefits. NAFE is a division of Working Mother Media and Bonnier Corporation.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara┬« (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...